On November 4, DexCom rose 5.42% in Regular Trading, trading at $87.18/share, with turnover of $51.00 million.
The move followed continued digestion of the company’s late-October quarterly report, which showed third-quarter results above expectations and a higher full-year revenue outlook, alongside a subsequent price-target increase from Barclays.
DexCom reported adjusted EPS of $0.73 on revenue of $1.344 billion for the September quarter, above consensus estimates of $0.67 and $1.327 billion. The company lifted its full-year revenue guidance to $5.20 billion-$5.25 billion from $5.18 billion-$5.25 billion. Additional follow-up commentary indicated US share gains, near-record global new patient additions, progress toward converting nearly 50% of the US installed base to the 15-day G7 sensor by year-end, and a planned Canada launch in November, reinforcing expectations for stronger growth visibility beyond the current year.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments